CRL

NEUTRALProduct

Charles River Laboratories Inte

2026-09-04

Price

$288.50

-1.65%

This is the 2026-09-04 snapshot — the signals and analysis for CRL as of this single trading day.

View full CRL research hub →

Score4.5Watchlist

Signals3/8 DNA0/13 Act · 0/4 Risk

SentimentNEUTRALScore: 7

Volume0.9xvs 20d avg

Analysis

The bullish divergence in Charles River Laboratories (CRL) is a textbook example of institutional absorption, where buyers are actively ignoring noise about legacy demand softness and insider selling in favor of the company's expansion into complex biologics. Recent news of the Medigen Vaccine Biologics collaboration for Next Generation Sequencing perfectly aligns with the stock's PERFECT_STACK and MARKET_LEADER technical signals, indicating strong accumulation. Buoyed by a RISK_ON macro regime that favors market leaders and brushes off headline panic, CRL's +7.2% relative strength signals high-conviction price discovery.

Fired Signals

GOLDEN CROSSMARKET LEADERPERFECT STACK

Key Takeaways

Actionable Thesis: Capitalize on the institutional momentum by establishing long positions, as technical signals confirm a breakout despite lingering negative headlines.
Key Risk: Elevated cancellations or prolonged demand softness in the legacy Discovery and Safety Assessment segments could weigh on organic growth.
What to Watch: Price action around the $277.00 support level and further commercial traction from the Medigen and Lilly collaborations.

← Back to 2026-09-04 View Full CRL History →Yahoo Finance &nearr;